Chardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX)
Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $52.00 price objective on the biotechnology company’s stock. A number of other research firms have also recently issued reports on RGNX. Morgan Stanley lifted their price […]
Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $52.00 price objective on the biotechnology company’s stock. A number of other research firms have also recently issued reports on RGNX. Morgan Stanley lifted their price […]
